Navigation Links
Express Scripts Unveils New Opportunities to Drive Down Healthcare Costs; Presents Five Studies at Academy of Managed Care Pharmacy Conference
Date:10/13/2010

ST. LOUIS, Oct. 13 /PRNewswire-FirstCall/ -- At the Academy of Managed Care Pharmacy (AMCP) 2010 Educational Conference taking place in St. Louis this week, Express Scripts (Nasdaq: ESRX) will present research findings that spotlight new opportunities for driving down healthcare costs and providing increased value for health plan sponsors and patients.

(Logo:  http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080827/EXPRESSSCRIPTSLOGO)

"Our new research identifies a specific set of opportunities for health plan sponsors and their members to reach healthier outcomes and lower costs," said Steven Miller, MD, senior vice president and chief medical officer at Express Scripts. "By turning data into insights, and insights into solutions, Express Scripts continues to lead the industry in making the use of prescription drugs safer and more affordable."  

During the event, George Paz, chairman, president and chief executive officer of Express Scripts, will address AMCP leadership and selected honorees at an awards luncheon. In addition, Brian Seiz, vice president of Clinical Services, will discuss electronic prescribing and therapy adherence during conference sessions.

Express Scripts' research includes three studies that support the use of lower-cost prescription drugs in two classes: anti-epileptics and antidepressants.

First is a study of the occurrence of seizures among patients switched between brand and generic anti-epileptic drugs. The study showed no significant relationship between a switch and exacerbation when controlling for important patient characteristics, consistent with earlier research findings. The effect was similar regardless of whether the new agent was a brand or generic anti-epileptic drug.

The company is also presenting two studies on antidepressants. One compares discontinuation rates and healthcare costs between patients starting brand and generic sertraline. Another examines discontinuation rates and costs between patients starting any brand or generic selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs).

Conclusions of the antidepressant studies included that the short-term costs of using brand versus generic sertraline were similar, and the costs of using any generic SSRIs and SNRIs were lower. Both studies found that the risks of discontinuation were similar in patients starting either a brand or generic antidepressant.

Express Scripts researchers are also presenting two additional studies at the conference:

  • An analysis of the effect of message framing on patients' decisions related to cost savings opportunities. In the study, patients who received letters that employed an illusion of progress message frame were more likely to choose to save on prescription costs by switching to a lower-cost alternative drug or moving a prescription from a retail pharmacy to home delivery. The principle of illusion of progress proposes that people behave differently the closer they get to an end goal or reward, and that they will accelerate a particular behavior to reach that point faster.
  • A study of a commercially insured cohort of breast cancer patients, describing the use of filgrastim and pegfilgrastim. These agents are used to improve tolerability of chemotherapy regimens. Researchers found that actual use of these agents often deviated from established treatment guidelines, including a substantial number of patients who received concurrent therapy with both agents. These concurrent users received a lower intensity of treatment, but were on therapy for a significantly longer period of time than those on either agent alone.

  • The AMCP 2010 Educational Conference is the largest assembly of pharmacy and healthcare professionals dedicated solely to the issues of managed-care pharmacy. It will highlight myriad activities, initiatives, breakthroughs and partnerships that are shaping the future of managed-care pharmacy. The conference attracts more than 2,500 attendees who are managed healthcare professionals interested in increasing their knowledge of the management and coordination of clinical, pharmacy benefit and pharmaceutical care programs.

    About Express Scripts

    Express Scripts, Inc., one of the largest pharmacy benefit management companies in North America, is leading the way toward creating better health and value for patients through Consumerology®, the advanced application of the behavioral sciences to healthcare. This approach is helping millions of members realize greater healthcare outcomes and lowering cost by assisting in influencing their behavior. Headquartered in St. Louis, Express Scripts provides integrated PBM services including network-pharmacy claims processing, home delivery services, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services. More information can be found at http://www.express-scripts.com and http://www.consumerology.com. Media Contact: Julie Adelsberger314.996.0991jcadelsberger@express-scripts.com
    '/>"/>

    SOURCE Express Scripts, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. NDRI Has Been Awarded $3.59 Million From the National Institutes of Health, The Directors Common Fund to Provide Human Tissue for GTEx, the New Genotype-Tissue Expression Project
    2. Express Scripts Announces Third Quarter 2010 Earnings and 2011 Earnings Guidance Conference Call
    3. Express Scripts Accurately Predicts Which Patients Are Likely to Ignore Doctors Orders
    4. Express Scripts Completes Spinoff of Rx Outreach
    5. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
    6. Express Scripts to Present at Barclays 2010 Global Healthcare Conference
    7. Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack
    8. Supelco(R) Introduces Breakthrough in Bioseparations Performance -- Ascentis(R) Express ES-C18 HPLC Columns
    9. Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity
    10. Bayer Express Your Simple Win Creativity Contest Grand Prize Winners Announced
    11. Help is Here Express in Orlando to Help Floridians Afford Medicine
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
    (Date:12/8/2016)... -- Research and Markets has announced the addition of ... Type, Application, Usability - Forecast to 2025" report to their ... , , ... to grow at a CAGR of around 3.2% from 2015 to ... include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in ...
    (Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
    Breaking Medicine Technology:
    (Date:12/9/2016)... PITTSBURGH, PA (PRWEB) , ... December 09, 2016 , ... ... treatments," said an inventor from Winchester, Va. "I thought that if the nebulizer had ... their treatments rather than fearing them." , He developed the patent-pending NEBY to avoid ...
    (Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
    (Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
    (Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
    (Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Medical Center has been recognized for adherence to the highest standards of ... medical accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , ...
    Breaking Medicine News(10 mins):